In this abstract we explain the compounding of bevacizumab eye drops for neovascularizacion, some studies have demonstrated their efficacy, It has 1 month stability. (Abstract Number: 3PC-013).

A. MONZON MORENO, M.L. MOYA MARTIN, F. GOMEZ DE RUEDA. Hospital Universitario Virgen Macarena, Sevilla (Spain)

Background and importance

Vascular endotelial growth factor (VEGF) is a mediator in the process of neovascularization in the cornea. VEGF inhibitors, such as, bevacizumab are currently one of the treatments of Neovascular Age-Related Macular Degeneration (AMD). Bevacizumab is a full-length humanized antibody against VEGF, and has been approved for use in oncology but is also widely used as an off-label treatment for choroidal neovascularization, central retina occlusion, proliferative diabetic retinopathy and iris neovascularization, with good results. Recently, the off-label use of topical as well as subconjuntival bevacizumab has been considered as a new treatment modality for corneal neovascularization

Aim and objectives

The compounding of bevacizumab eye drops in two different concentrations

Materials and methods:

Bevacizumab eye drops in a sterile compounding can be prepared in two different concentrations in vertical laminar flow hood in a sterile environment and applying the Good Manufacturing Practices:



Results:

Bevacizumab eye drops can easily prepared as a sterile compounding and used when the intravitreal syringes of bevacizumab are not appropriate for use.

Conclusion and relevance:

The off-label use of topical bevacizumab for corneal neovascularization is a option for patients with choroidal neovascularization, central retina occlusion, proliferative diabetic retinopathy, iris neovascularization and Age-Related Macular Degeneration.

References:

Dastjerdi MH, Al-Arfaj KM, Nallasasmy N et al. Khalid. Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, non-comparative study. Arch Ophthalmol, 2009, April;127(4):381-389.

Monzon Moreno A, Bevacizumab en el tratamiento de la degeneración macular neovascular asociada a la edad. Farm Hosp, 30 (2006):387-388.

Monzon Moreno A, Camean Fernandez M, Merino Bohorquez V et al. Intravitreal bevacizumab syringes. Working protocol. European journal of clinical pharmacy: atención farmacéutica,Vol.15,Nº5, 2013:351-357.

Monzon Moreno A et al. Ranibizumab y bevacizumab en el tratamiento del edema macular diabético. Agencia de Evaluación de Tecnologías Sanitarias de Andalucía. 2014.

Hospital Universitario Virgen Macarena

Junta de Andalucía
Consejería Salud y Consumo
Servicio Andaluz de Salud